ACR–ACNM–SNMMI–SPR–STR PRACTICE PARAMETER FOR THE PERFORMANCE OF PULMONARY SCINTIGRAPHY

PREAMBLE

I. INTRODUCTION

II. INDICATIONS AND CONTRAINDICATIONS

III. QUALIFICATIONS AND RESPONSIBILITIES OF PERSONNEL

IV. SPECIFICATIONS OF THE EXAMINATION

A. Pulmonary Perfusion Imaging

1. Radiopharmaceutical—Technetium-99m–labeled macroaggregated albumin (MAA) [12,13]

a. Administered Activity—Perfusion After Ventilation

IV. SPECIFICATIONS OF THE EXAMINATION

A. Pulmonary Perfusion Imaging

1. Radiopharmaceutical—Technetium-99m–labeled macroaggregated albumin (MAA) [12,13]

b. Administered Activity—Ventilation After Perfusion or Perfusion Only

IV. SPECIFICATIONS OF THE EXAMINATION

A. Pulmonary Perfusion Imaging

1. Radiopharmaceutical—Technetium-99m–labeled macroaggregated albumin (MAA) [12,13]

c. MAA Particle Size and Administered Number of Particles

IV. SPECIFICATIONS OF THE EXAMINATION

A. Pulmonary Perfusion Imaging

1. Radiopharmaceutical—Technetium-99m–labeled macroaggregated albumin (MAA) [12,13]

d. Radiopharmaceutical Administration

IV. SPECIFICATIONS OF THE EXAMINATION

A. Pulmonary Perfusion Imaging

1. Radiopharmaceutical—Technetium-99m–labeled macroaggregated albumin (MAA) [12,13]

e. Imaging

IV. SPECIFICATIONS OF THE EXAMINATION

B. Pulmonary Ventilation Imaging

1. Radiopharmaceutical—Technetium-99m-labeled diethylene-triamine pentacetic acid (DTPA) aerosol

IV. SPECIFICATIONS OF THE EXAMINATION

B. Pulmonary Ventilation Imaging

2. Radiopharmaceutical—Xenon-133

IV. SPECIFICATIONS OF THE EXAMINATION

B. Pulmonary Ventilation Imaging

2. Radiopharmaceutical—Xenon-133

a. Administered activity

IV. SPECIFICATIONS OF THE EXAMINATION

B. Pulmonary Ventilation Imaging

2. Radiopharmaceutical—Xenon-133

b. Imaging

IV. SPECIFICATIONS OF THE EXAMINATION

C. Other Considerations

V. DOCUMENTATION

VI. EQUIPMENT SPECIFICATIONS

VII. RADIATION SAFETY IMAGING

VIII. QUALITY CONTROL AND IMPROVEMENT, SAFETY, INFECTION CONTROL, AND PATIENT EDUCATION

ACKNOWLEDGEMENTS

REFERENCES